Neurogene Inc. (NGNE)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20260 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Neurogene Inc.’s names, not what it holds today.
2 published
1 published
1 published
Names not counted (2)
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Nov 27, 2025 | 2025/0361308 | NEO-2/15 Variants and Uses Thereof for Preferentially Stimulating T-Regulatory Cells | Biotechnology | Neurogene Inc. |
| Oct 26, 2023 | 2023/0340071 | Interleukin-2 Receptor Beta (IL-2RB) Binding Polypeptides | Biotechnology | Neoleukin Therapeutics, Inc. |
| Oct 19, 2023 | 2023/0331858 | COMBINATION THERAPY USING AN IL-2 RECEPTOR AGONIST AND AN IMMUNE CHECKPOINT INHIBITOR | Pharmaceuticals | NEOLEUKIN THERAPEUTICS, INC. |
| Nov 24, 2022 | 2022/0370563 | METHODS OF ADMINISTRATION OF IL-2 RECEPTOR AGONISTS | Pharmaceuticals | NEOLEUKIN THERAPEUTICS, INC. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.